Puma Biotechnology
PUMA decreases the growth of prostate cancer PC-3 cells independent of p53
PUMA is a cellular target of miR-BART5. (A) Target site of miR-BART5 in... | Download Scientific Diagram
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Puma Biotech: Wounded Predator Ready To Jump Back (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
EMA's oncology advisory group to render opinion on Puma Bio's neratinib next month; shares slip 2% after hours By Seeking Alpha
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
Puma Biotechnology
Puma Biotech: Wounded Predator Ready To Jump Back (NASDAQ:PBYI) | Seeking Alpha
2E) SAO/
PDF) Off-patent oral oncology drugs for kids (O3K FP7-project): from bedside to PUMA
Puma Biotechnology
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology | Business Wire
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Knight Therapeutics licences cancer drug from Puma Biotechnology
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today | The Motley Fool
